New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated partnership between Novo Nordisk and Hims & Hers.

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.

Review the current Novo Nordisk AS ADR (NVO:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if NVO is the best investment for you.

As rates of MASLD, which is linked to obesity and diabetes, rise, new therapies have emerged, but better diagnostic and ...